These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
665 related articles for article (PubMed ID: 14730536)
1. Pharmacological strategies for kidney function preservation: are there differences by ethnicity? Lakkis J; Weir MR Adv Ren Replace Ther; 2004 Jan; 11(1):24-40. PubMed ID: 14730536 [TBL] [Abstract][Full Text] [Related]
2. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. Flack JM; Peters R; Shafi T; Alrefai H; Nasser SA; Crook E J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S92-8. PubMed ID: 12819310 [TBL] [Abstract][Full Text] [Related]
3. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
4. Relationships of race and ethnicity to progression of kidney dysfunction and clinical outcomes in patients with chronic kidney failure. Lopes AA Adv Ren Replace Ther; 2004 Jan; 11(1):14-23. PubMed ID: 14730535 [TBL] [Abstract][Full Text] [Related]
5. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Whaley-Connell A; Sowers JR Kidney Int; 2017 Aug; 92(2):313-323. PubMed ID: 28341271 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease and its relationship with chronic kidney disease. Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487 [TBL] [Abstract][Full Text] [Related]
9. End-stage renal disease due to diabetes in racial/ethnic minorities and disadvantaged populations. Lopes AA Ethn Dis; 2009; 19(1 Suppl 1):S1-47-51. PubMed ID: 19484875 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology and risk factors for chronic kidney disease. McClellan WM Med Clin North Am; 2005 May; 89(3):419-45. PubMed ID: 15755460 [TBL] [Abstract][Full Text] [Related]
11. CKD and ESRD in US Hispanics. Desai N; Lora CM; Lash JP; Ricardo AC Am J Kidney Dis; 2019 Jan; 73(1):102-111. PubMed ID: 29661541 [TBL] [Abstract][Full Text] [Related]
12. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
13. Educational paper: Progression in chronic kidney disease and prevention strategies. Schaefer B; Wühl E Eur J Pediatr; 2012 Nov; 171(11):1579-88. PubMed ID: 22968936 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockade. Maione A; Strippoli GF Ethn Dis; 2009; 19(1 Suppl 1):S1-86-9. PubMed ID: 19484883 [TBL] [Abstract][Full Text] [Related]
15. Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD. Onuigbo MA Ren Fail; 2010; 32(8):954-8. PubMed ID: 20722563 [TBL] [Abstract][Full Text] [Related]
16. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Weir MR; Lakkis JI; Jaar B; Rocco MV; Choi MJ; Kramer HJ; Ku E Am J Kidney Dis; 2018 Dec; 72(6):873-884. PubMed ID: 30201547 [TBL] [Abstract][Full Text] [Related]